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Mechanistic aspects of mineralocorticoid receptor activation. scribed: the unliganded form (apo receptor) of the reti-
Aldosterone exerts its biological effects through binding to noid X receptor a (RXRa) and (thiazolidinedione)-per-
mineralocorticoid receptor (MR). Ligand binding induces a
oxisome proliferator-activated receptor g (PPARg) andreceptor transconformation within the ligand-binding domain
the agonist-bound form (holo receptor) of all-trans-reti-and dissociation of associated proteins from the receptor. The
ligand-activated receptor binds as a dimer to the response noic acid receptor g (RARg), thyroid receptor a (TRa),
elements present in the promoter region of target genes and estrogen receptor a (ERa), progesterone receptor (PR),
initiates the transcription through specific interactions with the
and PPARg [5–11]. All of these NR LBDs have a com-transcription machinery. The glucocorticoid hormone cortisol
mon fold, with 11 to 12 a helices (numbered H1 throughbinds to the human MR (hMR) with the same affinity as aldo-
sterone, but is less efficient than aldosterone in stimulating the H12) and one b turn arranged as an antiparallel a helical
hMR transactivation. The antimineralocorticoid spirolactones “sandwich” in a three-layer structure [12]. The LBDalso bind to the hMR but induce a receptor conformation that
adopts a more compact structure when a ligand is bound.is transcriptionally silent. In this report, we describe the key
residues involved in the recognition of agonist and antagonist The helix H11 is repositioned in continuity with H10,
ligands and propose a two-step model with a dynamic dimen- and helix H12, which encompasses the autonomous acti-
sion for the MR activation. In its unliganded state, MR is in an
vating domain (AF-2AD), is folded back toward theopened conformation in which folding into the ligand-binding
LBD core. The repositioning of H12, together with addi-competent state requires both the heat shock protein 90 and
the C-terminal part of the receptor. An intermediate complex tional structural changes, such as bending of H3, brings
is generated by ligand binding, leading to a more compact it into a distinct receptor environment, creating an inter-
receptor conformation. This transient complex is then con-
face suitable for NR coactivator binding [13]. Many co-verted to a transcriptionally active conformation in which sta-
activators that interact with the NRs in a ligand-depen-bility depends on the steroid-receptor contacts.
dent manner have been identified. These include steroid
receptor-coactivator 1 (SRC-1), transcriptional interme-
Aldosterone acts via a ligand-activated transcription diary factor II (TIF-II)/GRIP-1, receptor-interacting
factor, the mineralocorticoid receptor (MR). The MR is proteins of molecular weights 140 (RIP-140), TIF-1, and
a member of the nuclear receptor (NR) family that in- CBP/p300 [14, 15].
cludes receptors for steroid and thyroid hormones, vita- The aldosterone-dependent activation of gene tran-
min D3, and retinoic acids, as well as numerous orphan scription is thought to be a multistep process. Aldoste-
receptors for which no ligands are known [1–4]. MR has rone initially binds to MR and causes a receptor trans-
a modular structure comprising five regions (A through
conformation within the LBD that is believed to lead
E; Fig. 1). The N-terminal A/B region harbors an autono-
to the dissociation of the associated proteins from themous activation function. The central C-domain (DBD)
receptor [16, 17]. The ligand-activated receptor thenis highly conserved and is composed of two zinc fingers
binds, as a dimer, to the response elements in the pro-involved in DNA binding and receptor dimerization. A
moter regions of target genes and initiates hormone-hydrophilic region forms a hinge between the DBD and
mediated transcription through specific interactions withC-terminal ligand-binding domain (LBD). The LBD me-
the transcription machinery [18–20]. The way in whichdiates numerous functions, including ligand binding, in-
aldosterone acts through its own receptor has been ateraction with heat-shock proteins, dimerization, nuclear
targeting, and hormone-dependent activation. puzzle for some time for two main reasons: aldosterone
Several crystal structures of NR LBDs have been de- and cortisol both bind to the human MR (hMR) with
the same affinity, and the plasma glucocorticoid concen-
tration is 100- to 1000-fold higher than that of aldoste-Key words: aldosterone, antimineralocorticoid, steroid receptor, ligand
binding. rone. Consequently, most of the hMR should be occu-
pied by glucocorticoid, resulting in sodium retention.Ó 2000 by the International Society of Nephrology
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Table 1. Aldosterone dissociation constant at equilibrium (Kd) and
maximum number of aldosterone binding sites (N) for entire and
truncated human mineralocorticoid receptors (hMRs)
Kd NFig. 1. Schematic representation of the human mineralocorticoid re-
ceptor (hMR) structural organization. nmol/L
MR 0.5260.03 0.4360.13
MR 611–984 1.3460.13 0.4860.01
MR 729–984 2.9360.29 0.3860.02
MR 734–984 2.9060.62 0.1260.01The role of the 11b-hydroxysteroid dehydrogenase type
The entire or truncated hMRs were synthesized in vitro in rabbit reticulocyte2 (11bHSD2) in mineralocorticoid/glucocorticoid selec-
lysate. The lysate was diluted twofold with TEGWD buffer (20 mmol/L Tris-tivity has been established over the past decade [21, 22]. HCl, 1 mmol/L EDTA, 10% glycerol, 20 mmol/L sodium tungstate and 1 mmol/L
dithiothreitol, pH 7.4) and incubated with increasing concentrations (0.1 to 100This enzyme metabolizes 11b-hydroxylated-glucocorti-
nmol/L) of [3H]-aldosterone for four hours at 48C. Bound and unbound aldoste-coids (cortisol and corticosterone), but not aldosterone, rone were separated by dextran-charcoal and the Kd and N values were deter-
mined by computer analysis.into 11-keto derivatives (cortisone and 11-dehydrocorti-
costerone) that have a very low affinity for the MR [23].
This enzyme is present in aldosterone-sensitive tissues
[24, 25], and mutations that inactivate this enzyme are
and MR734-984 both have a lower affinity for aldoste-responsible for the syndrome of apparent mineralocorti-
rone than the entire receptor (Table 1). MR611-984,coid excess, resulting in sodium retention and severe
which is devoid of the A/B region, has an affinity similararterial hypertension [26]. Ex vivo experiments have re-
to that of the entire hMR (Table 1). Thus, the sequencevealed that the MR is more sensitive to aldosterone than
Thr-Ile-Ser-Arg-Ala (729 through 733) upstream of theto cortisol [27–31]. However, the mechanisms by which
LBD is required for hsp90 and steroid binding, and aMR is differentially stimulated by the two corticosteroid
longer sequence is needed for folding the receptor intohormones remain unknown.
a high-affinity hormone-binding state.The antimineralocorticoid spirolactones, synthetic ste-
Short segments of the C-terminal part of the receptorroids with a C17 g-lactone ring, have been used for the
were deleted because large truncations completely abol-past 30 years in the treatment of sodium-retaining states
ished its steroid-binding capacity. These mutant hMRsand as antihypertensive agents [32, 33]. Mineralocorti-
[MRD(C1), MRD(C2), MRD(C3), and MRD(C4)] lackcoid antagonists bind to the receptor with an affinity
the last one, two, three, or four amino acids [38]. Deletionidentical to that of aldosterone and induce a receptor
of the last one or two amino acids decreases aldosteroneconformation that is transcriptionally silent [17].
and cortisol binding by 30%, as well as the binding ofIn this report, we studied ligand–hMR interactions by
antagonists such as RU26752. Deletion of the last threeusing a three-dimensional model of the hMR-LBD [34],
amino acids [MRD(C3)] resulted in a 70% decrease inand analyzed the hMR activation process by examining
steroid binding, and deletion of the last four amino acidsthe ligand-induced hMR conformational changes and the
abolishes the steroid binding, although the interactionreceptor–coactivator interaction.
with hsp90 is not affected. The lack of ligand binding to
the carboxy-terminal truncated hMRs was due to mis-
FOLDING REQUIREMENTS OF hMR FOR folding of the receptor, as shown by the different sensitiv-
LIGAND BINDING ity to trypsin of MRD(C4) when compared with that of
On the basis of sequence homology among NRs, the the full-length receptor. These results support the idea
hMR-LBD has been defined as the sequence from posi- that a short sequence upstream the LBD is necessary
tion 734 to 984 [27]. However, this sequence has not been for the interaction of hMR with hsp90, and that hsp90
shown to be the minimum region that can bind agonists and the C terminus of hMR are both essential for folding
and antagonists. A series of mutant hMRs truncated at of the receptor into a ligand-binding competent state.
either the amino- or carboxy-terminal end of the recep-
tor was analyzed for its ability to bind agonists and antag-
IDENTIFICATION OF hMR AMINO ACIDSonists and to interact with the heat shock protein hsp90,
INTERACTING WITH MINERALOCORTICOIDa chaperone protein that is a prerequisite for ligand bind-
AGONISTS AND ANTAGONISTSing to hMR [35–37]. The MR-LBD (MR734-984) does
The crystal structure of the LBD of several NRs hasnot interact with hsp90 and has a lower aldosterone-
shown a common fold with 11 to 12 a helices and onebinding capacity than the entire receptor (Table 1). Add-
b turn arranged as an antiparallel a helical “sandwich”ing a short amino acid sequence, the five residues up-
in a three-layer structure [12]. As MR purification andstream of the LBD, led to a truncated receptor (MR729-
crystallization appeared to be very difficult, a three-dimen-984) that interacts with hsp90 and has the same aldoste-
rone-binding capacity as the entire hMR. MR729-984 sional model of the hMR-LBD has been constructed by
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Fig. 2. Human mineralocorticoid receptor
(hMR) steroid agonist (aldosterone, cortisol,
and dexamethasone) and antagonist (proges-
terone and RU26752) ligands.
Table 2. Steroid dissociation constant at equilibrium (Kd) for thetaking as a template the crystal structure of the human
wild-type and mutant hMRs
retinoic acid receptor g LBD (hRARg-LBD) [34] and
Aldosterone Cortisol Progesterone RU26752refined by using crystal structure of the human PR (Fa-
WT 0.5260.03 0.8760.13 1.0460.06 1.3160.31gart et al, manuscript in preparation). This model has
N770A UN UN 1.1960.05 NDallowed the pointing out of the amino acids delimiting
Q776A 6.7160.94 37610 5.8260.69 ND
the ligand-binding cavity. Two polar sites are located R817A 9.6960.80 UN 19.263.80 ND
T945A 3.8760.29 4.460.3 1.2160.05 NDat the extremities of the elongated hydrophobic ligand-
binding pocket. The site I is composed of Gln776 (helix Wild type (WT) and mutant hMRs were synthesized in the rabbit reticulocyte
lysate. The lysate was twofold diluted with TEGWD buffer and incubated withH3) and Arg817 (helix H5), and the site II comprises
increasing concentrations (0.1 to 100 nmol/L) of [3H]-aldosterone, [3H]-cortisol,
Asn770 (helix H3), Cys942, and Thr945 (helix H11). The [3H]-progesterone or [3H]-RU26752 for four hours at 48C. Bound and unbound
steroids were separated by charcoal-dextran and the Kd values were determinedorganization of the binding pocket is consistent with
by computer analysis. Abbreviations are: UN, undetected; ND, not determined.
the two polar extremities of aldosterone (the C3-ketone
group on the A-ring on one hand and the C20-ketone
and the C21-hydroxyl on the other hand). We replaced
polar residues of the ligand-binding pocket by alanine onists. Within the site II, Asn770 and Thr945 interact
with the 17 b-substituent of corticosteroids. Asn770 makesand tested the ability of the mutant hMRs (N770A,
Q776A, R817A, and T945A) to interact with steroids a hydrogen bond with the C21-hydroxyl group and the
18-hemiketal group, and the Thr945 g methyl group isselected for their agonist (aldosterone, cortisol) or antag-
onist (progesterone) properties and for their structures in a Van der Waals contact with the C21-hydroxyl group.
Thus, the agonist–hMR interaction is characterized by(Fig. 2). Aldosterone, cortisol, and progesterone have
the C3 ketone group in common. Aldosterone and corti- numerous contacts within the anchoring site II compared
with the antagonist–hMR interaction.sol are characterized by a C21 hydroxyl group, whereas
progesterone is lacking this hydroxyl group. Q776A and N770A, Q776A, and R817A were tested, by cotrans-
fection assays, for their ability to respond to aldosteroneR817A display a lower affinity for aldosterone, cortisol,
and progesterone compared with the wild-type hMR and cortisol. At a concentration of 1026 mol/L, cortisol
was unable to stimulate the transactivation function of(Table 2). Progesterone binds to T945A and N770A with
an affinity similar to that of the wild-type hMR. In con- N770A, Q776A, and R817A, whereas at this concentra-
tion, it maximally stimulated the wild-type hMR functiontrast, substitution of Thr945 by alanine decreased the
affinity of the receptor for aldosterone and cortisol, and (Fig. 3). Aldosterone was unable to stimulate the trans-
activation of N770A. In contrast, the aldosterone in-replacement of Asn770 by alanine completely abolished
the ability of hMR to bind aldosterone and cortisol. duced-transactivation activities of Q776A and R817A
were 25 and 75% that of the wild-type receptor, respec-These results altogether support the proposal that site I
and site II anchor the A-ring and D-ring, respectively. tively. These results are compatible with steroid-docking
studies that revealed that cortisol underwent an approxi-Within the site I, Gln776 and Arg817 interact with the
steroid C3-ketone group, common to agonists and antag- mate 408 rotation around its C3-C17 axis within the li-
Hellal-Levy et al: Mineralocorticoid receptor 1253
Fig. 3. Transcriptional activation of luciferase activity by wild-type and
mutant hMRs. COS-7 cells were transfected with wild-type or mutant-
hMR expression vectors, pFC31luc as the reporter plasmid, and a
b-galactosidase internal reporter to correct for transfection efficiency.
Before harvesting, cells were treated for 24 hours with 1026 mol/L
aldosterone (j) or cortisol ( ). Transactivation was determined by
luciferase activity, normalized to the internal b-galactosidase control,
and expressed as a percentage of wild-type activity at 1026 mol/L. Each
point is the mean 6 SEM of three separate experiments.
Fig. 4. Dissociation kinetics of [3H]-aldosterone (d), [3H]-cortisol (m),
and [3H]-RU26752 (j) from the wild-type hMR. Wild-type hMR was
produced by translation in vitro in the rabbit reticulocyte lysate. The
lysate was diluted twofold with TEGWD buffer and incubated with 10
gand-binding pocket of the hMR compared with aldoste- nmol/L [3H]-aldosterone [3H]-cortisol, or [3H]-RU26752 for 30 minutes
at 208C. The end of this incubation period was time zero for kineticrone [34].
analysis. The lysate was then divided into two. One sample was kept
at 208C to measure the stability of steroid-binding sites, and the other
was incubated with 1 mmol/L unlabeled aldosterone, cortisol, or RU26752.hMR ACTIVATION PROCESS Bound and free steroids were separated by dextran charcoal. Nonspe-
cific binding was measured in parallel incubations for each incubationThe structure of the LBD of several NRs has been
time. Results are corrected for receptor stability and are expressed asdescribed [5–11]. The major difference between the unli- a percentage of the binding measured at zero time.
ganded and agonist-associated structures is the reposi-
tioning of the helix H12 that is folded back toward the
LBD core in the agonist-associated conformation, creat-
with the backbone oxygen atom of Glu955, a residue ofing an interface suitable for NR coactivator binding [13].
the H11-H12 loop. The disrupting or loosening antago-As some distinct contacts are involved in the interaction
nist-receptor contacts probably destabilize helix H12of MR with agonists and antagonists, we wondered how
from its active position.these distinct contacts modulate the hMR activity.
It is worth emphasizing that glucocorticoids, such asAldosterone antagonists, such as progesterone and
cortisol and dexamethasone, exhibit an affinity for hMRRU26752, bind to hMR with an affinity of the same order
of the same order of magnitude as aldosterone (Tableof magnitude as that of aldosterone. Nevertheless, they
2, data not shown for dexamethasone). Nevertheless,dissociate more rapidly from the receptor than does aldo-
they dissociate more rapidly from the hMR than aldoste-sterone, indicating that antagonist-hMR complexes are
rone, a result illustrated in Figure 4 for cortisol. On theless stable than aldosterone-hMR complexes (Table 2
other hand, cis-trans-cotransfection assays revealed thatand Fig. 4). Proteolysis assays revealed that both agonist
hMR was more sensitive to aldosterone than to cortisoland antagonist binding to hMR induced changes in the
and dexamethasone [27–31]. The differences in the abil-LBD compaction [17]. Glutathione S transferase (GST)
ity of aldosterone and cortisol to stimulate hMR trans-pull-down experiments showed that agonist-associated
activation function are probably due to the distinct con-hMRs, but not unliganded or antagonist-associated hMR,
tacts involved in the interaction of hMR with aldosteroneare able to interact with RIP140, SRC1, and TIF-1a,
and cortisol. In fact, in addition to the 21 hydroxyl groupthree coactivators known to bind to NRs.
present in both steroids, aldosterone is characterized byWe propose that interactions between mineralocorti-
an 11-18 hemiketal group and cortisol by the 11b- andcoid agonists and hMR, especially between the C21-hy-
17a-hydroxyl groups.droxyl group and the residues Asn770 and Thr945, are
In conclusion, we propose that the hMR activationcrucial for the stabilization of the helix H12 in its active
state. The homology model revealed that the amide is a multistep process with a dynamic dimension. An
equilibrium model for hMR activation is proposed ingroup of the Asn770 residue makes a hydrogen bond
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Fig. 5. An equilibrium model for hMR acti-
vation. In the absence of hormone, the hMR
exists in a transcriptionally inactive conforma-
tion. After agonist binding, the receptor is
converted to a transient inactive conformation
and then to a transcriptionally active confor-
mation. The contacts between the hMR and
aldosterone in the helix H12 region stabilize
hMR in its active conformation. After antago-
nist binding, the receptor adopts the transient
inactive conformation. The loss of contacts
between hMR and antagonists prevents the
stabilization of H12 in its active position.
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